Figure 1 4.1.1 Cardiovascular outcomes in SGLT2 inhibitors: safety studies The EMPA-REG OUTCOME trial, which included 7020 patients with T2DM, was the first to demonstrate the cardiovascular protective effects of empagliflozin (54, 56)
Then gradually reintroduce carbohydrate restriction
The four large CDMOs (Bachem, AmbioPharm, CordenPharma, and PolyPeptide Group) are included for completeness
Key Areas Supported by Setria Glutathione The Setria Difference Defined by patented fermentation and rigorous quality standards, Setria delivers high purity and batch-to-batch consistency, supported by human clinical research
Dont eat too much at once
- Strategic global partnership: Zenas obtains exclusive global rights for autoimmune indications outside Greater China, while InnoCare retains global oncology rights and autoimmune indications within Greater China